NVAX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NV

Mkt Cap

$1.86B

Volume

9.34M

Next Earnings

November 5th

Loading chart

NV

NVAXNovavax Inc

NVAX

Pay with—

Available Balance0.00

NV

Mkt Cap

$1.86B

Volume

9.34M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to KnowNovavax stock closed at $12.82, up 1.26% and outperforming the broader market decline. The vaccine maker has surged 32.01% over the past month. However, upcoming earnings show mixed signals: EPS expected to improve 46.77% YoY to -$0.33, but revenue projected to fall 28.15% to $50.61 million. Full-year estimates show significant declines with -114.73% EPS change and -66.4% revenue decline. The stock holds a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Oct 13, 2026

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowNovavax has recently attracted investor attention with shares returning +18.4% over the past month, outperforming the S&P 500. However, the company faces significant headwinds including a projected loss of $0.38 per share for the current quarter and declining revenues expected to fall 66.4% for the current fiscal year. The stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.Zacks Investment Research · Oct 9, 2026

Novavax (NVAX) Stock Sinks As Market Gains: Here's WhyNovavax (NVAX) closed down 10.31% in recent trading. The vaccine maker faces headwinds with projected quarterly EPS of -$0.37 and revenue expected to decline 39.01% year-over-year to $42.96 million. Full-year estimates show -$0.46 EPS and $357.88 million revenue, representing significant declines. The stock holds a Zacks Rank #4 (Sell) rating with no recent changes to consensus estimates.Zacks Investment Research · Oct 6, 2026

Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.Zacks Investment Research · Oct 6, 2026

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to KnowNovavax stock closed at $10.11, up 1.1% and outpacing the S&P 500's 0.17% gain. However, the vaccine maker faces headwinds with projected quarterly revenue down 39.01% year-over-year and full-year revenue expected to decline 68.15%. The stock holds a Zacks Rank #3 (Hold) rating, with EPS estimates falling 7.86% over the past month.Zacks Investment Research · Sep 18, 2026

Is Cancer the Turnaround Moderna Has Been Looking for Post-COVID?Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.Zacks Investment Research · Sep 15, 2026

Novavax (NVAX) Laps the Stock Market: Here's WhyNovavax (NVAX) closed at $9.42, up 1.29%, outperforming the S&P 500's 0.86% gain. The stock has appreciated 14.25% over the past month. However, the company faces headwinds with projected quarterly EPS of -$0.22 and revenue expected to decline 39.01% year-over-year. Annual projections show -$0.47 EPS and 68.15% revenue decline. Novavax holds a Zacks Rank of #3 (Hold), with consensus EPS projections down 10.12% in the past 30 days.Zacks Investment Research · Sep 11, 2026

3 Reasons Not to Buy Into the Hantavirus-Related Biotech RallyA hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.The Motley Fool · May 13, 2026

What's Going On With Novavax Stock On Friday?Novavax stock surged 13.16% on Friday, tracking gains in Moderna following the publication of Phase 3 results for Moderna's mRNA-based seasonal flu vaccine in the New England Journal of Medicine. The article also notes Moderna's early-stage hantavirus vaccine research collaboration with the U.S. Army and Korea University. Novavax reported Q1 2025 sales of $139.51 million, beating estimates, though the company posted a net loss of $9 million compared to prior year income.Benzinga · May 8, 2026

This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?Novavax shares surged 28% in 2026 following a licensing deal with Pfizer for its Matrix-M adjuvant technology, worth $30M upfront plus up to $500M in milestones. However, the analyst recommends staying away from the stock due to uncertain core business fundamentals, inconsistent revenue from its coronavirus vaccine franchise, pipeline risks including a clinical hold setback, and significant competition in vaccine development.The Motley Fool · Jan 29, 2026

to start trading

NV

NVAXNovavax Inc

NVAX

Pay with—

Available Balance0.00

Your PositionYou don't own any NVAX yet.

Related Tickers

Earnings